Hyperprothrombinemia may result in acquired activated protein C resistance [2]

Blood

Volumn 96, Issue 9, 2000, Pages 3295-3296

  Tripodi, A ^a   Chantarangkul, V ^a   Mannucci, P M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

CONTROLLED STUDY; GENE MUTATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOGENESIS; VEIN THROMBOSIS; ACTIVATED PROTEIN C RESISTANCE; BLOOD; GENETICS; METABOLISM; POINT MUTATION;

ACTIVATED PROTEIN C RESISTANCE; FACTOR V; HUMANS; POINT MUTATION; PROTHROMBIN;

EID: 0034310731     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.3295     Document Type: Letter

References (12)

1. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
4. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
5. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
6. Familial thrombophilia and the prothrombin 20210A mutation: Association with increased thrombin generation and unusual thrombosis
7. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene
8. Inhibition of activated protein C anticoagulant activity by prothrombin
9. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
10. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay
11. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants
12. The influence of factor VIII on measurement of activated protein C resistance